Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged?for example, positronemitting radiopharmaceuticals.
Nuclear medicine is a medical specialty that allows modern diagnostics and treatments using radiopharmaceuticals original radiotracers. Radiopharmaceuticals are considered a special group of drugs and thus their preparation and use are regulated by a set of policies that have been adopted by individual member countries. In China, radioactive drug approval process is cumbersome, drug research and development cycle is too long and the high-end equipment of China mainly relies on imports, which restrict the development of nuclear medicine.
In application, nuclear medicine / radiopharmaceuticals is for treatment oncology, thyroid, cardiology and other dieses. The nuclear medicine / radiopharmaceuticals market is mainly driven by growing demand for treatment cardiology which accounts for nearly 42.19 % of total downstream consumption of Nuclear Medicine / Radiopharmaceuticals in China.
According to this study, over the next five years the Nuclear Medicine/Radiopharmaceuticals market will register a xx% CAGR in terms of revenue, the global market size will reach USD xx million by 2024, from USD xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Nuclear Medicine/Radiopharmaceuticals business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Nuclear Medicine/Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.
This study considers the Nuclear Medicine/Radiopharmaceuticals value and volume generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Diagnostic
Therapeutic
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Oncology
Thyroid
Cardiology
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
China Isotope & Radiation
Dongcheng
Jaco
Ciaeriar
Advanced Molecular-imaging Solution
Shanghai Atom Kexing
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Nuclear Medicine/Radiopharmaceuticals consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Nuclear Medicine/Radiopharmaceuticals market by identifying its various subsegments.
Focuses on the key global Nuclear Medicine/Radiopharmaceuticals manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Nuclear Medicine/Radiopharmaceuticals with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Nuclear Medicine/Radiopharmaceuticals submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
